Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246081 | 0.77 | TSHR (0.44) | TSHRCYP1A2KCNN4ALDH1A1MAPK1 | |
| SCHEMBL11315435 | 0.76 | KCNN4 (0.48) | TSHRCYP1A2KCNN4ALDH1A1MIF | |
| SCHEMBL9202415 | 0.73 | KCNN4 (0.39) | KCNN4ALDH1A1MAPK1 | |
| SCHEMBL3246877 | 0.73 | TSHR (0.44) | TSHRCYP1A2KCNN4ALDH1A1MIF | |
| SCHEMBL15129282 | 0.70 | TSHR (0.52) | TSHRCYP1A2KCNN4ALDH1A1MAPK1 | |
| SCHEMBL9574047 | 0.69 | TSHR (0.50) | TSHRCYP1A2KCNN4ALDH1A1MIF | |
| SCHEMBL3246631 | 0.68 | CYP2D6 (0.36) | TSHRCYP1A2KCNN4ALDH1A1MIF | |
| Hydrochloric Acid SCHEMBL7429032 | 0.67 | TSHR (0.48) | TSHRCYP1A2KCNN4ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL5388736 | 0.67 | KCNN4 (0.54) | TSHRCYP1A2KCNN4ALDH1A1MAPK1 | |
| SCHEMBL5199180 | 0.64 | TSHR (0.58) | TSHRCYP1A2KCNN4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | TSHR 2306/4885CYP1A2 1561/4885KCNN4 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.